Noura S. Abul-Husn, MD, PhD is Associate Professor of Medicine and Genetics, founding Chief of the Division of Genomic Medicine in the Department of Medicine, and Clinical Director of the Institute for Genomic Health at the Icahn School of Medicine at Mount Sinai.
Dr. Abul-Husn is a physician scientist working to uncover the clinical impact of human genetic variation in diverse populations and drive the equitable implementation of genomic medicine. Her scientific contributions include pioneering genome-first approaches in electronic health record-linked biobanks to provide novel clinical insights and inform therapeutic discovery. Her work has been published in leading journals, including Science, Cell, and the New England Journal of Medicine. Dr. Abul-Husn directs a genomic screening program tailored to the ancestrally diverse BioMe Biobank in New York City. As a principal investigator in the eMERGE (electronic Medical Records and Genomics) Network, she is leading efforts to integrate polygenic risk information into clinical care for diverse populations. Dr. Abul-Husn directs a new Genomic Health Clinic to provide the infrastructure for emerging genomic applications, and has initiated a Genomic Medicine Track for Internal Medicine residents to expand genomics knowledge across specialties.
Dr. Abul-Husn has a BSc Honors in Life Sciences and MSc in Pharmacology from Queen’s University in Canada. She completed her MD, PhD, and Internal Medicine/Medical Genetics residency at Mount Sinai in New York, and was elected to the Alpha Omega Alpha Medical Honor Society. She is board certified in Internal Medicine and Medical Genetics. Dr. Abul-Husn previously served as director of Translational Genetics at the Regeneron Genetics Center, during which time she received a 40 under 40 Rising Star Award. She is the recipient of the 2021 Dr. Michael S. Watson Genetic & Genomic Medicine Innovation Award from the ACMG Foundation for Genetic and Genomic Medicine.
- Describe how research biobanks embedded in health systems can drive genomic medicine
- Explain the utility of genomic data in identifying patients at high risk for disease
- Develop strategies to implement genomic medicine in diverse populations
- Noura S. Abul-Husn, MD, PhD
This seminar was delivered as a Pediatric Grand Rounds Lecture at Children’s Hospital of Philadelphia, on March 16, 2022.
The work presented in the presentations, videos, and other content on this site (“Presentations”) includes publicly available medical evidence, a consensus of medical practitioners, and/or opinions of individual practitioners that may differ from consensus opinions. These Presentations are intended only to provide general information and need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, the availability of various resources at the health care institution where the patient is located, and other factors. The Presentations are not intended to constitute medical advice or treatment, nor should they be relied upon as such. The Presentations are not intended to create a doctor-patient relationship between/among The Children’s Hospital of Philadelphia, its physicians and the individual patients in question. The information contained in these Presentations are general in nature, and do not and are not intended to refer to specific patients.
CHOP, The Children’s Hospital of Philadelphia Foundation and its or their affiliates, the authors, presenters, practitioners, editors, and others associated with the creation of the Presentations (“CHOP”) are not responsible for errors or omissions in the Presentations; for any outcomes a patient might experience where a clinician reviewed one or more such Presentations in connection with providing care for that patient; and/or for any and all third party content on the site or in the Presentations. CHOP makes no warranty, expressed or implied, with respect to the currency, completeness, applicability or accuracy of the Presentations. Application of the information in or to a particular situation remains the professional responsibility of the practitioner who is directly treating the patient.
To the extent that the Presentations include information regarding drug dosing, in view of ongoing research, changes in government regulations and the constant flow of information relating to drug therapy and drug reactions, the viewer should not rely on the Presentation content, but rather is urged to check the package insert for each drug for indications, dosage, warnings and precautions.
Some drugs and medical devices presented in the Presentations have United States Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the practitioner to ascertain the FDA status of each drug or device planned for use in their clinical practice.
You shall indemnify, defend and hold harmless CHOP, The Children’s Hospital of Philadelphia Foundation, and its/their current and former employees, officers, and agents, trustees, and their respective successors, heirs and assigns (“Indemnitees”) against any claims, liability, damage, loss or expenses (including attorneys’ fees and expenses of litigation) in connection with any claims, suits, actions, demands or judgments arising directly or indirectly out of your reference to or use of the Presentations.
The Presentations are protected by copyright laws and in some cases patent laws, and all rights are reserved under such laws. No part of the Presentations may be reproduced in any form by any means, or utilized in any other way, absent prior written permission from the copyright owner.
By starting this module, you agree to our Content Disclaimer and Terms of Service.